selected publications
-
academic article
- Senchenkova EYAnsari JBecker FVital SAAl-Yafeai ZSparkenbaugh EMPawlinski RStokes KYCarroll JLDragoi A-MQin CXRitchie RHSun HCuellar-Saenz HHRubinstein MRHan YWOrr AWPerretti MGranger DNGavins FNE. Novel Role for the AnxA1-Fpr2/ALX Signaling Axis as a Key Regulator of Platelet Function to Promote Resolution of Inflammation. Circulation. 140:319-335. 2019
- Qin CXRosli SDeo MCao NWalsh JTate MAlexander AEDonner DHorlock DLi RKiriazis HLee MKSBourke JEYang YMurphy AJDu X-JGao XMRitchie RH. Cardioprotective Actions of the Annexin-A1 N-Terminal Peptide, Ac2-26, Against Myocardial Infarction. Frontiers in Pharmacology. 10. 2019
- Bubb KJRitchie RHFigtree GA. Modified redox signaling in vasculature after chronic infusion of the insulin receptor antagonist, S961. Microcirculation. 26. 2019
- Deora GSQin CXVecchio EADebono AJPriebbenow DLBrady RMBeveridge JTeguh SCDeo MMay LTKrippner GRitchie RHBaell JB. Substituted Pyridazin-3(2H)-ones as Highly Potent and Biased Formyl Peptide Receptor Agonists. Journal of Medicinal Chemistry. 62:5242-5248. 2019
- Qin CXMay LTSexton PMDeBono AJBaell JBChristopoulos ARitchie RH. Correspondence: Reply to ‘Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury’. Nature Communications. 9. 2018
- Chandramouli CReichelt MECurl CLVarma UBienvenu LAKoutsifeli PRaaijmakers AJADe Blasio MJQin CXJenkins AJRitchie RHMellor KMDelbridge LMD. Diastolic dysfunction is more apparent in STZ-induced diabetic female mice, despite less pronounced hyperglycemia. Scientific Reports. 8. 2018
- Wanrooy BJKumar KPWen SWQin CXRitchie RHWong CHY. Distinct contributions of hyperglycemia and high-fat feeding in metabolic syndrome-induced neuroinflammation. Journal of Neuroinflammation. 15. 2018
- Bernardo BCGregorevic PRitchie RHMcMullen JR. Generation of MicroRNA-34 sponges and tough decoys for the heart: Developments and challenges. Frontiers in Pharmacology. 9. 2018
- Marwick THRitchie RShaw JEKaye D. Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. Journal of the American College of Cardiology. 71:339-351. 2018
- Sharma ATate MMathew GVince JERitchie RHde Haan JB. Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications. Frontiers in Physiology. 9:1-15. 2018
- Ng HHLeo CHParry LJRitchie RH. Relaxin as a therapeutic target for the cardiovascular complications of diabetes. Frontiers in Pharmacology. 9. 2018
- Spallotta FCencioni CAtlante SGarella DCocco MMori MMastrocola RKuenne CGuenther SNanni SAzzimato VZukunft SKornberger ASürün DSchnütgen FVon Melchner HDi Stilo AAragno MBraspenning MVan Criekinge WDe Blasio MJRitchie RHZaccagnini GMartelli FFarsetti AFleming IBraun TBeiras-Fernandez ABotta BCollino MBertinaria MZeiher AMGaetano C. Stable oxidative cytosine modifications accumulate in cardiac mesenchymal cells from type 2 diabetes patients: Rescue by α-ketoglutarate and TET-TDG functional reactivation. Circulation Research. 122:31-46. 2018
- Tate MGrieve DJRitchie RH. Are targeted therapies for diabetic cardiomyopathy on the horizon?. Clinical Science. 131:897-915. 2017
- Baltos J-AVecchio EAHarris MAQin CXRitchie RHChristopoulos AWhite PJMay LT. Capadenoson, a clinically trialed partial adenosine A 1 receptor agonist, can stimulate adenosine A 2B receptor biased agonism. Biochemical Pharmacology. 135:79-89. 2017
- Qin CXFinlayson SBAl-Sharea ATate MDe Blasio MJDeo MRosli SPrakoso DThomas CJKiriazis HGould EYang YHMorand EFPerretti MMurphy AJDu X-JGao X-MRitchie RH. Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo. Scientific Reports. 7:1-14. 2017
- Qin CXSleaby RDavidoff AJBell JRDe Blasio MJDelbridge LMChatham JCRitchie RH. Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications. Pharmacological Research. 116:45-56. 2017
- Tate MDeo MCao AHHood SGHuynh KKiriazis HDu X-JJulius TLFigtree GADusting GJKaye DMRitchie RH. Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat. Diabetes and Vascular Disease Research. 14:423-433. 2017
- Ritchie RHZerenturk EJPrakoso DCalkin AC. Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy. Journal of Molecular Endocrinology. 58:R225-R240. 2017
- Chin KYQin CMay LRitchie RHWoodman OL. New pharmacological approaches to the prevention of myocardial ischemia-reperfusion injury. Current Drug Targets. 18:1689-1711. 2017
- Prakoso DDe Blasio MJQin CRosli SKiriazis HQian HDu X-JWeeks KLGregorevic PMcMullen JRRitchie RH. Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clinical Science. 131:1345-1360. 2017
- Ng HHLeo CHPrakoso DQin CRitchie RHParry LJ. Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes. Scientific Reports. 7. 2017
- Qin CXMay LTLi RCao NRosli SDeo MAlexander AEHorlock DBourke JEYang YHStewart AGKaye DMDu X-JSexton PMChristopoulos AGao X-MRitchie RH. Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. Nature Communications. 8. 2017
- Bubb KJKok CTang ORasko NBBirgisdottir ABHansen TRitchie RBhindi RReisman SAMeyer CWard KKarimi Galougahi KFigtree GA. The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling. Free Radical Biology and Medicine. 108:585-594. 2017
- Sharma ARizky LStefanovic NTate MRitchie RHWard KWde Haan JB. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction. Cardiovascular Diabetology. 16. 2017
- Ritchie RHDrummond GRSobey CGDe Silva TMKemp-Harper BK. The opposing roles of NO and oxidative stress in cardiovascular disease. Pharmacological Research. 116:57-69. 2017
- De Blasio MJRamalingam ACao AHPrakoso DYe J-MPickering RWatson AMDde Haan JBKaye DMRitchie RH. The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy. Behavioural Processes. 807:12-20. 2017
- Tare MKalidindi RSRBubb KJParkington HCBoon W-MLi XSobey CGDrummond GRRitchie RHKemp-Harper BK. Vasoactive actions of nitroxyl (HNO) are preserved in resistance arteries in diabetes. Naunyn-Schmiedebergs Archives of Pharmacology. 390:397-408. 2017
- Kahlberg NQin CXAnthonisz JJap ENg HHJelinic MParry LJKemp-Harper BKRitchie RHLeo CH. Adverse vascular remodelling is more sensitive than endothelial dysfunction to hyperglycaemia in diabetic rat mesenteric arteries. Pharmacological Research. 111:325-335. 2016
- Delbridge LMDBenson VLRitchie RHMellor KM. Diabetic Cardiomyopathy: The Case for a Role of Fructose in Disease Etiology. Diabetes. 65:3521-3528. 2016
- Chin KYMichel LQin CXCao NWoodman OLRitchie RH. The HNO donor Angeli’s salt offers potential haemodynamic advantages over NO or dobutamine in ischaemia–reperfusion injury in the rat heart ex vivo. Pharmacological Research. 104:165-175. 2016
- Kemp-Harper BKHorowitz JDRitchie RH. Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure. Drugs. 76:1337-1348. 2016
- De Blasio MJHuynh KQin CRosli SKiriazis HAyer ACemerlang NStocker RDu X-JMcMullen JRRitchie RH. Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110α) signaling. Free Radical Biology and Medicine. 87:137-147. 2015
- Qin CYang YHMay LGao XStewart AGTu YWoodman OLRitchie RH. Cardioprotective potential of annexin-A1 mimetics in myocardial infarction. Pharmacology and Therapeutics. 148:47-65. 2015
- Cao NWong YGRosli SKiriazis HHuynh KQin CDu X-JKemp-Harper BKRitchie RH. Chronic Administration of the Nitroxyl Donor 1-Nitrosocyclo Hexyl Acetate Limits Left Ventricular Diastolic Dysfunction in a Mouse Model of Diabetes Mellitus In Vivo. Circulation: Heart Failure. 8:572-581. 2015
- Bowden MATesch GHJulius TLRosli SLove JERitchie RH. Earlier onset of diabesity-Induced adverse cardiac remodeling in female compared to male mice. Obesity. 23:1166-1177. 2015
- Huynh KBernardo BCMcMullen JRRitchie RH. Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacology and Therapeutics. 142:375-415. 2014
- Chin KYQin CCao NKemp-Harper BKWoodman OLRitchie RH. The concomitant coronary vasodilator and positive inotropic actions of the nitroxyl donor Angeli's salt in the intact rat heart: contribution of soluble guanylyl cyclase-dependent and -independent mechanisms. British Journal of Pharmacology. 171:1722-1734. 2014
- Fender ACPavic GDrummond GRDusting GJRitchie RH. Unexpected anti-hypertrophic responses to low-level stimulation of protease-activated receptors in adult rat cardiomyocytes. Naunyn-Schmiedebergs Archives of Pharmacology. 387:1001-1007. 2014
- Joshi MSBerger PJKaye DMPearson JTBauer JARitchie RH. Functional relevance of genetic variations of endothelial nitric oxide synthase and vascular endothelial growth factor in diabetic coronary microvessel dysfunction. Clinical and Experimental Pharmacology and Physiology. 40:253-261. 2013
- Irvine JCCao NGossain SAlexander AELove JEQin CHorowitz JDKemp-Harper BKRitchie RH. HNO/cGMP-dependent antihypertrophic actions of isopropylamine-NONOate in neonatal rat cardiomyocytes: potential therapeutic advantages of HNO over NO˙. American Journal of Physiology: Heart and Circulatory Physiology. 305:H365-H377. 2013
- Ritchie RHLeo CHQin CStephenson EJBowden MABuxton KDLessard SJRivas DAKoch LGBritton SLHawley JAWoodman OL. Low intrinsic exercise capacity in rats predisposes to age-dependent cardiac remodeling independent of macrovascular function. American Journal of Physiology: Heart and Circulatory Physiology. 304:H729-H739. 2013
- Mellor KMBell JRRitchie RHDelbridge LMD. Myocardial insulin resistance, metabolic stress and autophagy in diabetes. Clinical and Experimental Pharmacology and Physiology. 40:56-61. 2013
- Qin CBuxton KDPepe SCao AHVenardos KLove JEKaye DMYang YHMorand EFRitchie RH. Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-A1 and its N-terminal-derived peptide Ac-ANX-A12-26. British Journal of Pharmacology. 168:238-252. 2013
- Huynh KKiriazis HDu X-JLove JEGray SPJandeleit-Dahm KAMcMullen JRRitchie RH. Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radical Biology and Medicine. 60:307-317. 2013
- Dautov RFNgo DTMLicari GLiu SSverdlov ALRitchie RHKemp-Harper BKHorowitz JDChirkov YY. The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness. Nitric Oxide: Biology and Chemistry. 35:72-78. 2013
- Ritchie RHLove JEHuynh KBernardo BCHenstridge DCKiriazis HTham YKSapra GQin CCemerlang NBoey EJHJandeleit-Dahm KDu X-JMcMullen JR. Enhanced phosphoinositide 3-kinase(p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia. 55:3369-3381. 2012
- Irvine JCGanthavee VLove JEAlexander AEHorowitz JDStasch J-PKemp-Harper BKRitchie RH. The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy. PLoS ONE. 7:e44481-e44481. 2012
- Huynh KKiriazis HDu X-JLove JEJandeleit-Dahm KAForbes JMMcMullen JRRitchie RH. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia. 55:1544-1553. 2012
- Lin EQIrvine JCCao AHAlexander AELove JEPatel RMcMullen JRKaye DMKemp-Harper BKRitchie RH. Nitroxyl (HNO) Stimulates Soluble Guanylyl Cyclase to Suppress Cardiomyocyte Hypertrophy and Superoxide Generation. PLoS ONE. 7:e34892-e34892. 2012
- Mellor KMWendt IRRitchie RHDelbridge LMD. Fructose diet treatment in mice induces fundamental disturbance of cardiomyocyte Ca2+ handling and myofilament responsiveness. American Journal of Physiology: Heart and Circulatory Physiology. 302:H964-H972. 2012
- Sourris KCHarcourt BETang PHMorley ALHuynh KPenfold SACoughlan MTCooper MENguyen T-VRitchie RHForbes JM. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radical Biology and Medicine. 52:716-723. 2012
- Mellor KMBell JRWendt IRDavidoff AJRitchie RHDelbridge LMD. Fructose Modulates Cardiomyocyte Excitation-Contraction Coupling and Ca2+ Handling In Vitro. PLoS ONE. 6:e25204-e25204. 2011
- Mellor KMBell JRYoung MJRitchie RHDelbridge LMD. Myocardial autophagy activation and suppressed survival signaling is associated with insulin resistance in fructose-fed mice. Journal of Molecular and Cellular Cardiology. 50:1035-1043. 2011
- Sverdlov ALNgo DTMNightingale AKRajendran SMishra KHeresztyn TRitchie RHMarwick THFrenneaux MPHorowitz JD. The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. Nitric Oxide: Biology and Chemistry. 25:41-46. 2011
- Smith NJChan H-WQian HBourne AMHannan KMWarner FJRitchie RHPearson RBHannan RDThomas WG. Determination of the Exact Molecular Requirements for Type 1 Angiotensin Receptor Epidermal Growth Factor Receptor Transactivation and Cardiomyocyte Hypertrophy. Hypertension. 57:973-980. 2011
- Xu QDalic AFang LKiriazis HRitchie RHSim KGao X-MDrummond GSarwar MZhang Y-YDart AMDu X-J. Myocardial oxidative stress contributes to transgenic beta(2)-adrenoceptor activation-induced cardiomyopathy and heart failure. British Journal of Pharmacology. 162:1012-1028. 2011
- Bullen MLMiller AAAndrews KLIrvine JCRitchie RHSobey CGKemp-Harper BK. Nitroxyl (HNO) as a vasoprotective signaling molecule. Antioxidants and Redox Signaling. 14:1675-1686. 2011
- Mellor KRitchie RHMeredith GWoodman OLMorris MJDelbridge LMD. High-fructose diet elevates myocardial superoxide generation in mice in the absence of cardiac hypertrophy. Nutrition. 26:842-848. 2010
- Huynh KMcMullen JRJulius TLTan JWLove JECemerlang NKiriazis HDu XJRitchie RH. Cardiac-Specific IGF-1 Receptor Transgenic Expression Protects Against Cardiac Fibrosis and Diastolic Dysfunction in a Mouse Model of Diabetic Cardiomyopathy. Diabetes. 59:1512-1520. 2010
- Mellor KMRitchie RHDavidoff AJDelbridge LMD. Elevated dietary sugar and the heart: experimental models and myocardial remodeling. Canadian Journal of Physiology and Pharmacology. 88:525-540. 2010
- Mellor KMRitchie RHDelbridge LMD. Reactive oxygen species and insulin-resistant cardiomyopathy. Clinical and Experimental Pharmacology and Physiology. 37:222-228. 2010
- Ritchie RHIrvine JCRosenkranz ACPatel RWendt IRHorowitz JDKemp-Harper BK. Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond. Pharmacology and Therapeutics. 124:279-300. 2009
- Ritchie RRosenkranz AKaye D. B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target. Current Molecular Medicine. 9:814-825. 2009
- Venardos KMZatta AJMarshall TRitchie RKaye DM. Reduced L-arginine transport contributes to the pathogenesis of myocardial ischemia-reperfusion injury. Journal of Cellular Biochemistry. 108:156-168. 2009
- Porrello ERBell JRSchertzer JDCurl CLMcMullen JRMellor KMRitchie RHLynch GSHarrap SBThomas WGDelbridge LMD. Heritable pathologic cardiac hypertrophy in adulthood is preceded by neonatal cardiac growth restriction. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology. 296:R672-R680. 2009
- Irvine JCRitchie RHFavaloro JLAndrews KLWiddop REKemp-Harper BK. Nitroxyl (HNO): the Cinderella of the nitric oxide story. Trends in Pharmacological Sciences. 29:601-608. 2008
- Woodman OLMalakul WCao AHXu QRitchie RH. Atrial natriuretic peptide prevents diabetes-induced endothelial dysfunction. Life Sciences. 82:847-854. 2008
- Ritchie RHQuinn JMCao AHDrummond GRKaye DMFavaloro JMProietto JDelbridge LMD. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. Journal of Molecular and Cellular Cardiology. 42:1119-1128. 2007
- Goh SSCWoodman OLPepe SCao AHQin CRitchie RH. The Red Wine Antioxidant Resveratrol Prevents Cardiomyocyte Injury Following Ischemia-Reperfusion Via Multiple Sites and Mechanisms. Antioxidants and Redox Signaling. 9:101-113. 2007
- LASKOWSKI AWOODMAN OCAO ADRUMMOND GMARSHALL TKAYE DRITCHIE R. Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovascular Research. 72:112-123. 2006
- Ritchie RHZeitz CJWuttke RDHii JTYHorowitz JD. Attenuation of the Negative Inotropic Effects of Metoprolol at Short Cycle Lengths in Humans. Journal of the American College of Cardiology. 48:1234-1241. 2006
- Garreffa AMWoodman OLCao AHRitchie RH. Sodium Nitroprusside Protects Adult Rat Cardiac Myocytes From Cellular Injury Induced by Simulated Ischemia. Journal of Cardiovascular Pharmacology. 47:1-8. 2006
- Ritchie RHGordon JMWoodman OLCao AHDusting GJ. Annexin-1 peptide Anx-12-26 protects adult rat cardiac myocytes from cellular injury induced by simulated ischaemia. British Journal of Pharmacology. 145:495-502. 2005
- Ritchie RHRosenkranz ACHuynh LPStephenson TKaye DMDusting GJ. Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling. American Journal of Physiology: Heart and Circulatory Physiology. 287:H1179-H1185. 2004
- Rosenkranz ACHood SGWoods RLDusting GJRitchie RH. B-Type Natriuretic Peptide Prevents Acute Hypertrophic Responses in the Diabetic Rat Heart: Importance of Cyclic GMP. Diabetes. 52:2389-2395. 2003
- Candido RForbes JMThomas MCThallas VDean RGBurns WCTikellis CRitchie RHTwigg SMCooper MEBurrell LM. A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural Changes. Circulation Research. 92:785-792. 2003
- Ritchie RRosenkranz A. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovascular Research. 57:515-522. 2003
- Ritchie RHSun XBilszta JLGulluyan LMDusting GJ. Cardioprotective actions of an N-terminal fragment of annexin-1 in rat myocardium in vitro. Behavioural Processes. 461:171-179. 2003
- Gordon JMDusting GJWoodman OLRitchie RH. Cardioprotective action of CRF peptide urocortin against simulated ischemia in adult rat cardiomyocytes. American Journal of Physiology: Heart and Circulatory Physiology. 284:H330-H336. 2003
- Rosenkranz ACHood SGWoods RLDusting GJRitchie RH. Acute Antihypertrophic Actions of Bradykinin in the Rat Heart. Hypertension. 40:498-503. 2002
- Rosenkranz ACDusting GJRitchie RH. Endothelial Dysfunction Limits the Antihypertrophic Action of Bradykinin in Rat Cardiomyocytes. Journal of Molecular and Cellular Cardiology. 32:1119-1126. 2000
- Zeitz CJRitchie RHJarrett RGHii JTYWuttke RDHorowitz JD. The Positive Inotropic Effects of Milrinone But Not of Digoxin are Attenuated at Short Cycle Lengths. Journal of Cardiovascular Pharmacology. 35:427-433. 2000
- Ritchie RHMarsh JDSchiebinger RJ. Bradykinin-stimulated protein synthesis by myocytes is dependent on the MAP kinase pathway and p70S6K. American Journal of Physiology: Heart and Circulatory Physiology. 276:H1393-H1398. 1999
- Ritchie RHMarsh JDSchiebinger RJ. Bradykinin-stimulated protein synthesis by myocytes is dependent on the MAP kinase pathway and p70(S6K). American Journal of Physiology: Heart and Circulatory Physiology. 276:H1393-H1398. 1999
- Ritchie RHSchiebinger RJLapointe MCMarsh JD. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. American Journal of Physiology: Heart and Circulatory Physiology. 275. 1998
- Ritchie RHSchiebinger RJLapointe MCMarsh JD. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. American Journal of Physiology: Heart and Circulatory Physiology. 275:H1370-H1374. 1998
- Ritchie RHSchiebinger RJLapointe MCMarsh JD. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. American Journal of Physiology: Heart and Circulatory Physiology. 275:H1370-H1374. 1998
- Ritchie RHorowitz RHRAJD. ELIMINATION, BUT NOT ACCUMULATION, OF METOPROLOL BY RAT ISOLATED PERFUSED HEART IS SELECTIVELY IMPAIRED BY HYPOXIA. Clinical and Experimental Pharmacology and Physiology. 25:548-551. 1998
- Marsh JDLehmann MHRitchie RHGwathmey JKGreen GESchiebinger RJ. Androgen Receptors Mediate Hypertrophy in Cardiac Myocytes. Circulation. 98:256-261. 1998
- Ritchie RHHii JTYHorowitz JD. Relationship Between Myocardial Milrinone Content and Its Acute Hemodynamic and Electrophysiologic Effects. Journal of Cardiovascular Pharmacology. 31:885-893. 1998
- Ritchie RHSallustio BCHii JTYHorowitz JD. Short-Term Myocardial Uptake of d- and l-Sotalol in Humans: Relation to Hemodynamic and Electrophysiologic Effects. Journal of Cardiovascular Pharmacology. 31:876-884. 1998
- Ritchie RHMorgan DJHorowitz JD. Myocardial Effect Compartment Modeling of Metoprolol and Sotalol: Importance of Myocardial Subsite Drug Concentration. Journal of Pharmaceutical Sciences. 87:177-182. 1998
- Ritchie RHMarsh JDLancaster WDDiglio CASchiebinger RJ. Bradykinin Blocks Angiotensin II–Induced Hypertrophy in the Presence of Endothelial Cells. Hypertension. 31:39-44. 1998
- Ritchie RHWuttke RDHii JTYJarrett RGCarey ALHorowitz JD. The force-interval relationship of the left ventricle: A quantitative description in patients with ischemic heart disease. Journal of Cardiac Failure. 1:273-284. 1995
- Zhang YIRitchie RHHorowitz JD. Postextrasystolic potentiation in patients with ischaemic heart disease: influence of inotropic agents.. British Journal of Clinical Pharmacology. 40:25-30. 1995
- Ritchie RHWuttke RDStafford IHorowitz JD. Relation Between Acute Myocardial Uptake and Hemodynamic and Electrocardiograpic Effects of Metoprolol in Humans. Journal of Cardiovascular Pharmacology. 23:57-57. 1994
-
conference paper
- Ritchie RH. Evidence for a Causal Role of Oxidative Stress in the Myocardial Complications of Insulin Resistance. Heart Lung and Circulation. 11-18. 2009
- Ritchie RHDelbridge LMD. CARDIAC HYPERTROPHY, SUBSTRATE UTILIZATION AND METABOLIC REMODELLING: CAUSE OR EFFECT?. Clinical and Experimental Pharmacology and Physiology. 159-166. 2006
- Dusting ARGRitchie R. HYPERGLYCAEMIA ABOLISHES THE ANTIHYPERTROPHIC EFFICACY OF BRADYKININ IN RAT VENTRICULAR MYOCYTES. Clinical and Experimental Pharmacology and Physiology. 519-521. 1999
- Ritchie RHSun XDusting GJ. LIPOCORTIN-1 PRESERVES MYOCARDIAL RESPONSIVENESS TO beta-ADRENERGIC STIMULATION IN RAT PAPILLARY MUSCLE. Clinical and Experimental Pharmacology and Physiology. 522-524. 1999
-
erratum
- Qin CXFinlayson SBAl-Sharea ATate MDe Blasio MJDeo MRosli SPrakoso DThomas CJKiriazis HGould EYang YHMorand EFPerretti MMurphy AJDu X-JGao X-MRitchie RH. Author Correction: Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo. Scientific Reports. 7185. 2018